Previous Close | 0.5000 |
Open | 0.4500 |
Bid | 0.0500 |
Ask | 0.2000 |
Strike | 4.00 |
Expire Date | 2024-09-20 |
Day's Range | 0.4500 - 0.5000 |
Contract Range | N/A |
Volume | |
Open Interest | 72 |
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024.
On May 13, 2024, Steven Galson, a Director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 21,940 shares of the company, as reported in a recent SEC Filing.
Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 13, 2024.